Innate Pharma Cash Flow Reinvestment Rate
Innate Pharma cash flow reinvestment rate. Innate Pharma (IPHA) has a Cash Flow Reinvestment Rate of 0.09x as of June 2024, reinvesting $283.00K (capex $283.00K ) from operating cash flow of $3.04 Million. Explore Innate Pharma cash debt coverage ratio to assess how comfortably operating cash covers total debt obligations.
Reinvestment Rate
Total Reinvested
Operating Cash Flow
Capital Expenditures
Cash Flow Reinvestment Rate of Innate Pharma (2006–2019)
Cash flow reinvestment rate of Innate Pharma from 2006 to 2019. Historical reinvestment intensity for Innate Pharma across 4 annual periods. Explore Innate Pharma capital reinvestment ratio to see what proportion of operating cash flow is directed to capital expenditures.
Innate Pharma Cash Flow Reinvestment Rate by Year (2006–2019)
Innate Pharma cash flow reinvestment rate by year from 2006 to 2019. Year-by-year capital reinvestment analysis for Innate Pharma. For the full cash flow conversion analysis, see IPHA cash generation efficiency.
| Year | Reinvestment Rate | Total Reinvested (USD) | Operating CF | Capex | YoY Change |
|---|---|---|---|---|---|
| 2019 | 3.65x | $127.52 Million | $34.92 Million | $65.40 Million | ▲ +469.8% |
| 2015 | 0.64x | $133.24 Million | $207.91 Million | $7.40 Million | ▲ +2484.4% |
| 2011 | 0.02x | $322.00K | $12.99 Million | $322.00K | ▼ -98.8% |
| 2006 | 2.09x | $752.00K | $360.00K | $752.00K | — |